Drugs News and Research

RSS

Genetic source of muscular dystrophy blocked

Researchers at the University of Rochester Medical Center have found a way to block the genetic flaw at the heart of a common form of muscular dystrophy. The results of the study, which were published today in the journal Science, could pave the way for new therapies that essentially reverse the symptoms of the disease.

17 Jul 2009

Genome sequencing of schistosomiasis parasites could promote drug development

Researchers have sequenced the genomes of two parasites that cause bilharzia or schistosomiasis - a disease transmitted by water-borne snails that affects more than 200 million people worldwide - "revealing potential weaknesses that could be exploited by drug developers," Nature reports (Smith, 7/15).

16 Jul 2009

WHO gives up counting swine flu cases

In its latest briefing on the H1N1 influenza A pandemic (swine flu), the World Health Organisation (WHO) says the unprecedented speed of the spread of the virus means reporting requirements and the data needed for risk assessment, both within affected countries and at the global level, are changing.

16 Jul 2009

Cystic fibrosis medicines that help to break down mucus in the lungs may carry an unexpected long-term benefit

Cystic fibrosis medicines that help to break down mucus in the lungs may carry an unexpected long-term benefit, a study suggests.

16 Jul 2009

FDA approves Onsolis pain reliever for cancer patients

The U.S. Food and Drug Administration today approved Onsolis, medication intended for certain patients with cancer to help manage breakthrough pain – severe flares of pain that break through regular pain medication.

16 Jul 2009

Discovery of key protein for tumor suppression in ER+ breast cancer

Researchers from the Kimmel Cancer Center at Jefferson have identified a protein relationship that may be an ideal treatment target for ER+ breast cancer. The study was reported in the July 15 issue of Cancer Research.

15 Jul 2009

House Democrats' health bill would tax rich to finance insurance expansion

House Democratic leaders Tuesday unveiled their bill to reform America's health care system - and insure an additional 37 million Americans over the next 10 years - to the tune of more than $1 trillion, funded mostly through an up-to-5.4 percent surtax on income for the wealthiest Americans, The Washington Post reports.

15 Jul 2009

Bio manufacturers poised to follow Senate victory with house win

"A veteran California lawmaker with ties to the biotechnology industry said she thinks her proposal to protect brand-name biologic makers has enough support to carry in the House Energy and Commerce Committee," Dow Jones Newswires/Wall Street Journal reports.

15 Jul 2009

NPR examines Obama's 'broad' global health strategy; maternal health in Afghanistan discussed at congressional briefing

NPR reports on President Obama's "broad global health strategy," which would increase the amount of funding for family planning, maternal and child health programs to about a "half billion dollars" next year. According to NPR, "the U.S. has committed $230 million [over the next five years] directly to health in Afghanistan, whose government has already built 2,000 health facilities since the collapse of the Taliban regime" (Wilson, 7/15).

15 Jul 2009

GlaxoSmithKline pledges $97 million investment in AIDS drugs for Africa, allows South African drugmaker to produce generic second-line treatment

GlaxoSmithKline (GSK) on Tuesday announced plans to invest $97 million over 10 years "to improve research, development and access to AIDS drugs in Africa," Reuters reports.

15 Jul 2009

Review of Brazil's HIV/AIDS treatment programs shows importance of generic drugs, researchers say

"Brazil has been successful in its nearly 20-year effort to treat people living with" HIV/AIDS, and generic medicines have been "a large part of the solution," according to a recent Health Affairs review, UPI reports (UPI, 7/14).

15 Jul 2009

Prevalence of artemisinin monotherapies raising risk of resistence

Almost half of all artemisinin manufacturers and malaria-endemic countries are "failing to comply" with WHO requirements to sell the treatment in combination with other drugs, which is increasing the risk that malaria parasites will develop resistance to artemsinin, Nature reports.

15 Jul 2009

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Schering-Plough Corporation has announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment.

15 Jul 2009

Discovery of new mechanism controlling neuronal migration

The molecular machinery that helps brain cells migrate to their correct place in the developing brain has been identified by scientists at St. Jude Children's Research Hospital.

15 Jul 2009

New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy

Cancer Research Technology (CRT), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, Cancer Research UK, Cardiff University and The Institute of Cancer Research (ICR) are set to begin a major new research collaboration for the first time. This will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.

15 Jul 2009

Focusing HIV treatment helps control concurrent hepatitis B infection

Prolonged use of highly active antiretroviral therapy (HAART) to treat people infected with both HIV and hepatitis B (HBV) helps to better control the hepatitis B infection and could delay or prevent liver complications, according to a new study by researchers at Wake Forest University School of Medicine.

15 Jul 2009

HELP Committee approves protection for high tech drug companies from generics

"Senators agreed Monday to give high-tech biologic drugs 12 years of market protection before generic versions can compete," according to The Associated Press.

15 Jul 2009

Novartis to partner with OneWorld Health to develop diarrhea drug

"Swiss drug company Novartis AG and the Institute for OneWorld Health, a nonprofit group, will announce this week a partnership to discover drugs for a type of diarrhea that kills about 1.6 million children each year in the developing world," the Wall Street Journal reports.

15 Jul 2009

Why oral contraceptives fail for obese women

Researchers have identified a potential biological mechanism that could explain why oral contraceptives may be less effective at preventing pregnancy in obese women, as some epidemiological studies have indicated.

14 Jul 2009

Developing countries can successfully combat HIV/AIDS epidemic with generics

Brazil's nearly two-decade effort to treat people living with HIV and AIDS shows that developing countries can successfully combat the epidemic. Inexpensive generic medicines are a large part of the solution, say researchers from Brown University and the Harvard School of Public Health.

14 Jul 2009